ResearchMoz

Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) potentially supplemented by approvals for Alzheimers disease

GBI Research
Published Date » 2013-05-03
No. Of Pages » N/A
   
 GBI Research’s report: Immunoglobulin Market to 2019 provides in-depth analysis of the global immunoglobulin market. The report analyzes the markets for immunoglobulin products in the US, the top five European countries (the UK, Germany, France, Italy and Spain) and Japan. The revenue and annual cost of therapy are forecast for the key geographies and in seven key therapeutic segments, along with epidemiology data, until 2019.  
   
 The seven key therapeutic segments are Primary Immunodeficiency (PI), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Multifocal Motor Neuropathy (MMN), Guillain-Barré Syndrome (GBS), Myasthenia Gravis (MG), Idiopathic Thrombocytopenic Purpura (ITP), and Chronic Lymphocytic Leukemia (CLL). The report also profiles the...
Table of Content

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Immunoglobulins Market to 2019 - Introduction
2.1 Overview

3 Immunoglobulins Market to 2019 - Market Overview
3.1 Revenue
3.2 Annual Cost of Therapy
3.3 Immunoglobulins Market Drivers and Restraints
3.3.1 Market Drivers
3.3.2 Restraints

4 Immunoglobulins Market to 2019 - Geographical Landscape
4.1 US
4.1.1 Revenue
4.1.2 Annual Cost of Therapy
4.2 Top Five European Countries
4.2.1 Revenue
4.2.2 Annual Cost of Therapy
4.3 Japan
4.3.1 Revenue
4.3.2 Annual Cost of Therapy

5 Immunoglobulins Market to 2019 - Therapeutic Landscape
5.1 Main Therapeutic Indications
5.1.1 Indicated Conditions for Intravenous Immunoglobulin Usage - US
5.1.2 Indications for Intravenous Immunoglobulin Usage - Europe
5.1.3 Guidelines for Intravenous Immunoglobulin Usage - UK
5.1.4 Indications for Intravenous Immunoglobulin Usage - Japan
5.2 Revenue Share for the Major Therapeutic Indications
5.3 Primary Immunodeficiency Market
5.3.1 Introduction
5.3.2 Revenue
5.3.3 Annual Cost of Therapy
5.3.4 Epidemiology
5.3.5 Current Use
5.3.6 Geographical Segmentation
5.4 Guillain-Barré Syndrome Market
5.4.1 Introduction
5.4.2 Revenue
5.4.3 Annual Cost of Therapy
5.4.4 Epidemiology
5.4.5 Current Use for Therapies
5.4.6 Geographical Segmentation
5.5 Chronic Lymphocytic Leukemia Market
5.5.1 Introduction
5.5.2 Revenue
5.5.3 Annual Cost of Therapy
5.5.4 Epidemiology
5.5.5 Current Use
5.5.6 Geographical Segmentation
5.6 Chronic Inflammatory Demyelinating Polyneuropathy Market
5.6.1 Introduction
5.6.2 Revenue
5.6.3 Annual Cost of Therapy
5.6.4 Epidemiology
5.6.5 Current Use
5.6.6 Geographical Segmentation
5.7 Myasthenia Gravis Market
5.7.1 Introduction
5.7.2 Revenue
5.7.3 Annual Cost of Therapy
5.7.4 Epidemiology
5.7.5 Current Use
5.7.6 Geographical Segmentation
5.8 Multifocal Motor Neuropathy Market
5.8.1 Introduction
5.8.2 Revenue
5.8.3 Annual Cost of Therapy
5.8.4 Epidemiology
5.8.5 Current Use
5.8.6 Geographical Segmentation
5.9 Idiopathic Thrombocytopenic Purpura
5.9.1 Introduction
5.9.2 Revenue
5.9.3 Annual Cost of Therapy
5.9.4 Epidemiology
5.9.5 Current Use
5.9.6 Geographical Segmentation

6 Immunoglobulins Market to 2019 - Profiles of Marketed Products
6.1 Overview
6.2 Privigen
6.2.1 Overview
6.2.2 Approved Indications
6.2.3 Safety
6.2.4 Efficacy
6.3 Gammagard S/D
6.3.1 Overview
6.3.2 Approved Indications
6.3.3 Safety
6.3.4 Efficacy
6.4 Gammagard Liquid
6.4.1 Overview
6.4.2 Approved Indications
6.4.3 Safety
6.4.4 Efficacy
6.5 Octagam 5%
6.5.1 Overview
6.5.2 Approved Indications
6.5.3 Safety
6.5.4 Efficacy
6.6 Flebogamma 10% DIF
6.6.1 Overview
6.6.2 Approved Indications
6.6.3 Safety
6.6.4 Efficacy
6.7 Gamunex-C
6.7.1 Overview
6.7.2 Approved Indications
6.7.3 Safety
6.7.4 Efficacy
6.8 Gammaplex
6.8.1 Overview
6.8.2 Approved Indications
6.8.3 Safety
6.8.4 Efficacy
6.9 HyQvia
6.9.1 Overview
6.9.2 Approved Indications
6.9.3 Safety
6.9.4 Efficacy
6.10 Bivigam
6.10.1 Overview
6.10.2 Approved Indications
6.10.3 Safety
6.10.4 Efficacy

7 Immunoglobulins Market to 2019 - Pipeline Analysis
7.1 Research and Development Pipeline
7.2 Major Pipeline Product Profiles
7.2.1 IVIG3I Grifols 10%
7.2.2 RI-002 (IVIG)

8 Immunoglobulins Market to 2019 - Competitive Landscape
8.1 Baxter International Inc.
8.1.1 Business Description
8.1.2 Recent Developments
8.2 Biotest Pharmaceuticals
8.2.1 Business Description
8.2.2 Recent Developments
8.3 Bio Products Laboratory Ltd.
8.3.1 Business Description
8.3.2 Recent Developments
8.4 CSL Behring Limited
8.4.1 Business Description
8.4.2 Recent Developments
8.5 Grifols S.A.
8.5.1 Business Description
8.5.2 Recent Developments
8.6 Octapharma AG
8.6.1 Business Description
8.6.2 Recent Developments

9 Immunoglobulins Market to 2019 - M&A and Licensing Deals Landscape
9.1 M&A Deals
9.1.1 Grifols Buys 60% of Progenika Biopharma
9.1.2 Grifols Acquires 40% of the Capital of Biotechnology Firm VCN Bioscience
9.1.3 Grifols Purchases Three Plasma Donation Centers in the US from Canada’s Cangene
9.1.4 Baxter Enhances Renal Therapies Portfolio with Acquisition of Gambro
9.2 R&D Licensing Agreements
9.2.1 Baxter and Onconova Announce European Licensing Agreement for Anti-Cancer Compound Rigosertib
9.2.2 Baxter Announces Collaboration with Sanquin to Expand Capacity for Plasma Therapies
9.2.3 Baxter Announces 20 Year Partnership with Hemobras in Brazil

10 Immunoglobulins Market to 2019 - Asia-Pacific and China
10.1 India
10.1.1 Overview
10.1.2 Regulatory Landscape
10.1.3 National Institute for Biologicals
10.1.4 Marketed Products
10.1.5 Product Profiles
10.1.6 Company Profiling
10.2 China
10.2.1 Overview
10.2.2 Regulatory Information
10.2.3 Marketed Products
10.2.4 Company Profiling
10.3 Australia
10.3.1 Overview
10.3.2 Regulatory Landscape
10.3.3 Marketed Products
10.3.4 Product Profiles
10.3.5 Company Profiling

11 Global Immunoglobulins Market: Appendix
11.1 Market Definitions
11.2 Abbreviations
11.3 References
11.4 Research Methodology
11.4.1 Coverage
11.4.2 Secondary Research
11.4.3 Primary Research
11.4.4 Expert Panel Validation
11.5 Contact Us
11.6 Disclaimer

List of Tables


Table 1: Immunoglobulins Market, Top Seven Markets, Revenue ($bn), 2006-2012
Table 2: Immunoglobulins Market, Top Seven Markets, Revenue Forecast ($bn), 2012-2019
Table 3: Immunoglobulins Market, Top Seven Markets, Annual Cost of Therapy ($), 2006-2012
Table 4: Immunoglobulins Market, Top Seven Markets, Annual Cost of Therapy Forecast ($), 2012-2019
Table 5: Immunoglobulins Market, US, Revenue ($bn), 2006-2012
Table 6: Immunoglobulins Market, US, Revenue Forecast ($bn), 2012-2019
Table 7: Immunoglobulins Market, US, Annual Cost of Therapy ($), 2006-2012
Table 8: Immunoglobulins Market, US, Annual Cost of Therapy Forecast ($), 2012-2019
Table 9: Immunoglobulins Market, Top Five European Countries, Revenue ($m), 2006-2012
Table 10: Immunoglobulins Market, Top Five European Countries, Revenue Forecast ($m), 2012-2019
Table 11: Immunoglobulins Market, Top Five European Countries, Annual Cost of Therapy ($), 2006-2012
Table 12: Immunoglobulins Market, Top Five European Countries, Annual Cost of Therapy Forecast ($), 2012-2019
Table 13: Immunoglobulins Market, Japan, Revenue ($m), 2006-2012
Table 14: Immunoglobulins Market, Japan, Revenue Forecast ($m), 2012-2019
Table 15: Immunoglobulins Market, Japan, Annual Cost of Therapy ($), 2006-2012
Table 16: Immunoglobulins Market, Japan, Annual Cost of Therapy Forecast ($), 2012-2019
Table 17: Immunoglobulins Market, US, Approved Indications for IVIG Usage, 2012
Table 18: Immunoglobulins Market, EU, Indicated Conditions for IVIG Usage, 2012
Table 19: Immunoglobulins Market, UK, Guidelines for IVIG Usage, 2012
Table 20: Immunoglobulins Market, Top Seven Markets, PI, Revenue ($bn), 2006-2012
Table 21: Immunoglobulins Market, Top Seven Markets, PI, Revenue Forecast ($bn), 2012-2019
Table 22: Immunoglobulins Market, Top Seven Markets, PI, Annual Cost of Therapy ($), 2006-2012
Table 23: Immunoglobulins Market, Top Seven Markets, PI, Annual Cost of Therapy Forecast ($),
2012-2019
Table 24: Immunoglobulins Market, Top Seven Markets, PI, Epidemiology, 2006-2012
Table 25: Immunoglobulins Market, Top Seven Markets, PI, Epidemiology Forecast, 2012-2019
Table 26: Immunoglobulins Market, Top Seven Markets, PI, Geographical Revenue ($m), 2006-2012
Table 27: Immunoglobulins Market, Top Seven Markets, PI, Geographical Revenue Forecast ($m),
2012-2019
Table 28: Immunoglobulins Market, Top Seven Markets, GBS, Revenue ($m), 2006-2012
Table 29: Immunoglobulins Market, Top Seven Markets, GBS, Revenue Forecast ($m), 2012-2019
Table 30: Immunoglobulins Market, Top Seven Markets, GBS, Annual Cost of Therapy ($), 2006-2012
Table 31: Immunoglobulins Market, Top Seven Markets, GBS, Annual Cost of Therapy Forecast ($),
2012-2019
Table 32: Immunoglobulins Market, Top Seven Markets, GBS, Epidemiology, 2006-2012
Table 33: Immunoglobulins Market, Top Seven Markets, GBS, Epidemiology Forecast, 2012-2019
Table 34: Immunoglobulins Market, Top Seven Markets, GBS, Geographical Revenue ($m), 2006-2012
Table 35: Immunoglobulins Market, Top Seven Markets, GBS, Geographical Revenue Forecast ($m),
2012-2019
Table 36: Immunoglobulins Market, Top Seven Markets, CLL, Revenue ($m), 2006-2012
Table 37: Immunoglobulins Market, Top Seven Markets, CLL, Revenue Forecast ($m), 2012-2019
Table 38: Immunoglobulins Market, Top Seven Markets, CLL, Annual Cost of Therapy ($), 2006-2012
Table 39: Immunoglobulins Market, Top Seven Markets, CLL, Annual Cost of Therapy Forecast ($),
2012-2019
Table 40: Immunoglobulins Market, Top Seven Markets, CLL, Epidemiology, 2006-2012
Table 41: Immunoglobulins Market, Top Seven Markets, CLL, Epidemiology Forecast, 2012-2019
Table 42: Immunoglobulins Market, Top Seven Markets, CLL, Geographical Revenue ($m), 2006-2012
Table 43: Immunoglobulins Market, Top Seven Markets, CLL, Geographical Revenue Forecast ($m),
2012-2019
Table 44: Immunoglobulins Market, Top Seven Markets, CIDP, Revenue ($m), 2006-2012
Table 45: Immunoglobulins Market, Top Seven Markets, CIDP, Revenue Forecast ($m), 2012-2019
Table 46: Immunoglobulins Market, Top Seven Markets, CIDP, Annual Cost of Therapy ($), 2006-2012
Table 47: Immunoglobulins Market, Top Seven Markets, CIDP, Annual Cost of Therapy Forecast ($),
2012-2019
Table 48: Immunoglobulins Market, Top Seven Markets, CIDP, Epidemiology, 2006-2012
Table 49: Immunoglobulins Market, Top Seven Markets, CIDP, Epidemiology Forecast, 2012-2019
Table 50: Immunoglobulins Market, Top Seven Markets, CIDP, Geographical Revenue ($m), 2006-2012
Table 51: Immunoglobulins Market, Top Seven Markets, CIDP, Geographical Revenue Forecast ($m),
2012-2019
Table 52: Immunoglobulins Market, Top Seven Markets, MG, Revenue ($m), 2006-2012
Table 53: Immunoglobulins Market, Top Seven Markets, MG, Revenue Forecast ($m), 2012-2019
Table 54: Immunoglobulins Market, Top Seven Markets, MG, Annual Cost of Therapy ($), 2006-2012
Table 55: Immunoglobulins Market, Top Seven Markets, MG, Annual Cost of Therapy Forecast ($),
2012-2019
Table 56: Immunoglobulins Market, Top Seven Markets, MG, Epidemiology, 2006-2012
Table 57: Immunoglobulins Market, Top Seven Markets, MG, Epidemiology Forecast, 2012-2019
Table 58: Immunoglobulins Market, Top Seven Markets, MG, Geographical Revenue ($m), 2006-2012
Table 59: Immunoglobulins Market, Top Seven Markets, MG, Geographical Revenue Forecast ($m),
2012-2019
Table 60: Immunoglobulins Market, Top Seven Markets, MMN, Revenue ($m), 2006-2012
Table 61: Immunoglobulins Market, Top Seven Markets, MMN, Revenue Forecast ($m), 2012-2019
Table 62: Immunoglobulins Market, Top Seven Markets, MMN, Annual Cost of Therapy ($), 2006-2012
Table 63: Immunoglobulins Market, Top Seven Markets, MMN, Annual Cost of Therapy Forecast ($),
2012-2019
Table 64: Immunoglobulins Market, Top Seven Markets, MMN, Epidemiology, 2006-2012
Table 65: Immunoglobulins Market, Top Seven Markets, MMN, Epidemiology Forecast, 2012-2019
Table 66: Immunoglobulins Market, Top Seven Markets, MMN, Geographical Revenue ($m), 2006-2012
Table 67: Immunoglobulins Market, Top Seven Markets, MMN, Geographical Revenue Forecast ($m), 2012-2019
Table 68: Immunoglobulins Market, Top Seven Markets, ITP, Revenue ($m), 2006-2012
Table 69: Immunoglobulins Market, Top Seven Markets, ITP, Revenue Forecast ($m), 2012-2019
Table 70: Immunoglobulins Market, Top Seven Markets, ITP, Annual Cost of Therapy ($), 2006-2012
Table 71: Immunoglobulins Market, Top Seven Markets, ITP, Annual of Cost Therapy Forecast ($),
2012-2019
Table 72: Immunoglobulins Market, Top Seven Markets, ITP, Epidemiology, 2006-2012
Table 73: Immunoglobulins Market, Top Seven Markets, ITP, Epidemiology Forecast, 2012-2019
Table 74: Immunoglobulins Market, Top Seven Markets, ITP, Geographical Revenue ($m), 2006-2012
Table 75: Immunoglobulins Market, Top Seven Markets, ITP, Geographical Revenue Forecast ($m),
2012-2019
Table 76: Immunoglobulins Market, US, FDA-Approved IVIG Products by Therapeutic Indication,
1994-2013
Table 77: Immunoglobulins Market, Top Five European Countries, EMA-Approved IVIG Products by Therapeutic Indication, 2004-2013
Table 78: Immunoglobulins Market, Global, Phase III Pipeline Molecules, 2013
Table 79: Immunoglobulins Market, Global, Alzheimer’s Disease, Pipeline Molecules, 2013
Table 80: Immunoglobulins Market, Grifols, Global, Marketed Immunoglobulin Products, 2013
Table 81: Immunoglobulins Market, India, PI, Marketed Products, 2013
Table 82: Immunoglobulins Market, India, GBS, Marketed Products, 2013
Table 83: Immunoglobulins Market, India, CLL, Marketed Products, 2013
Table 84: Immunoglobulins Market, India, CIDP, Marketed Products, 2013
Table 85: Immunoglobulins Market, India, ITP, Marketed Products, 2013
Table 86: Immunoglobulins Market, India, Reliance Life Sciences, Key Pipeline Products, 2012-2013
Table 87: Immunoglobulins Market, India, Zydus Cadila, Key Marketed Products, 2012-2013
Table 88: Immunoglobulins Market, India, Sun Pharmaceuticals, Generic Versions of Key Marketed Products, 2012-2013
Table 89: Immunoglobulins Market, China, Blood and Blood Products Industry, 1985-2012
Table 90: Immunoglobulins Market, Australia, IVIG Issued to Patients, by Therapeutic Indication, 2011
Table 91: Immunoglobulins Market, Australia, Marketed Products, CIDP, 2013
Table 92: Immunoglobulins Market, Australia, Marketed Products, CLL, 2013
Table 93: Immunoglobulins Market, Australia, Marketed Products, GBS, 2013
Table 94: Immunoglobulins Market, Australia, Marketed Products, ITP, 2013
Table 95: Immunoglobulins Market, Australia, Marketed Products, PI, 2013

List of Figures


Figure 1: Immunoglobulins Market, Top Seven Markets, Revenue Forecast ($bn), 2006-2019
Figure 2: Immunoglobulins Market, Top Seven Markets, Annual Cost of Therapy Forecast ($), 2006-2019
Figure 3: Immunoglobulins Market, US, Revenue Forecast ($bn), 2006-2019
Figure 4: Immunoglobulins Market, US, Annual Cost of Therapy Forecast ($), 2006-2019
Figure 5: Immunoglobulins Market, Top Five European Countries, Revenue Forecast ($m), 2006-2019
Figure 6: Immunoglobulins Market, Top Five European Countries, Annual Cost of Therapy ($), 2006-2019
Figure 7: Immunoglobulins Market, Japan, Revenue Forecast ($m), 2006-2019
Figure 8: Immunoglobulins Market, Japan, Annual Cost of Therapy ($), 2006-2019
Figure 9: Immunoglobulins Market, Top Seven Markets, Market Share by Therapeutic Indication (%), 2012
Figure 10: Immunoglobulins Market, Top Seven Markets, PI, Revenue Forecast ($bn), 2006-2019
Figure 11: Immunoglobulins Market, Top Seven Markets, PI, Annual Cost of Therapy Forecast ($),
2006-2019
Figure 12: Immunoglobulins Market, Top Seven Markets, PI, Geographical Revenue Forecast ($m),
2006-2019
Figure 13: Immunoglobulins Market, Top Seven Markets, GBS, Revenue Forecast ($m), 2006-2019
Figure 14: Immunoglobulins Market, Top Seven Markets, GBS, Annual Cost of Therapy Forecast ($),
2006-2019
Figure 15: Immunoglobulins Market, Top Seven Markets, GBS, Geographical Revenue Forecast ($m),
2006-2019
Figure 16: Immunoglobulins Market, Top Seven Markets, CLL, Revenue Forecast ($m), 2006-2019
Figure 17: Immunoglobulins Market, Top Seven Markets, CLL, Annual Cost of Therapy Forecast ($),
2006-2019
Figure 18: Immunoglobulins Market, Top Seven Markets, CLL, Geographical Revenue Forecast ($m),
2006-2019
Figure 19: Immunoglobulins Market, Top Seven Markets, CIDP, Revenue Forecast ($m), 2006-2019
Figure 20: Immunoglobulins Market, Top Seven Markets, CIDP, Annual Cost of Therapy Forecast ($),
2006-2019
Figure 21: Immunoglobulins Market, Top Seven Markets, CIDP, Geographical Revenue Forecast ($m),
2006-2019
Figure 22: Immunoglobulins Market, Top Seven Markets, MG, Revenue Forecast ($m), 2006-2019
Figure 23: Immunoglobulins Market, Top Seven Markets, MG, Annual Cost of Therapy Forecast ($),
2006-2019
Figure 24: Immunoglobulins Market, Top Seven Markets, MG, Geographical Revenue Forecast ($m),
2006-2019
Figure 25: Immunoglobulins Market, Top Seven Markets, MMN, Revenue Forecast ($m), 2006-2019
Figure 26: Immunoglobulins Market, Top Seven Markets, MMN, Annual Cost of Therapy Forecast ($),
2006-2019
Figure 27: Immunoglobulins Market, Top Seven Markets, MMN, Geographical Revenue Forecast ($m), 2006-2019
Figure 28: Immunoglobulins Market, Top Seven Markets, ITP, Revenue Forecast ($m), 2006-2019
Figure 29: Immunoglobulins Market, Top Seven Markets, ITP, Annual Cost of Therapy Forecast ($),
2006-2019
Figure 30: Immunoglobulins Market, Top Seven Markets, ITP, Geographical Revenue Forecast ($m),
2006-2019
Figure 31: Immunoglobulins Market, US, FDA-Approved Products by Therapeutic Indication, 2003-2013
Figure 32: Immunoglobulins Market, Australia, IVIG Issued (g/1,000 population), 2006-2012
Figure 33: Immunoglobulins Market, Australia, IVIG Issued to Patients, by Therapeutic Indication, 2011

Upcoming Reports:

Internet Of Things (IoT) And Machine-To-Machine (M2M) Communication Market - Global Industry Analysis, Size, Share, Trends, Analysis, Growth And Forecast, 2013 - 2019
By - Transparency Market Research
The global Internet of Things (IoT) and Machine-To-Machine (M2M) market is expected to grow at a substantial growth rate. Rising demand for cloud apps, wireless networks, and sensors, is affecting the growth of this market. The factors driving the IoT and M2M market rely on the government support, and enhancing connectivity.  The global Internet of Things (IoT) and Machine-To-Machine (M2M) market is segmented into four major categories, on the basis of technology and platforms into Radio frequency identification (RFID), Sensor nodes, Gateways, Cloud management, Near field...
Coal Handling Equipment Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
By - Transparency Market Research
Coal handling is the initial process of power generation in every coal fired power plant. From its unloading at the plant site to its subsequent firing in the boiler furnace, the coal goes through a number of preparation and storage phases. These systems are an integral part of the overall coal quality management system and material flow of the power plant. Due to the large number of procedures and equipment’s involved in the coal handling phase, the overall number of possible players in the market is substantial. There are a large number of market drivers propelling both old and...
Nuclear Energy Market - Global Industry Analysis, Size, Share, Trends, Analysis, Growth And Forecast, 2013 - 2019
By - Transparency Market Research
Nuclear reactors are used to produce electricity across the world. The heat produced by controlled fission chain reaction in nuclear reactors is used to create steam pressure. This steam pressure is used to drive a power- generating turbine. Currently nuclear reactors are used to produce approximately 19% of the world’s total electricity production. Nuclear reactor market is expected to grow in future due to several under construction, planned and proposed nuclear reactor projects. Nuclear energy market can be segmented on the base of technology into Boiling Water Reactor...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Under Armour Makes US$475 Million Deal for MyFitnessPal
Feb 26, 2015  
Baltimore based Under Armour has made earnest attempts in becoming one of the largest players in the fitness apparel market. In their latest venture, the company bought out MyFitnessPal for US$475 million on February 4, 2015. The company also purchased a smaller running app Endomondo for US$85 million. MyFitnessPal is a free fitness app that allows a user to keep a track of his/her...
Hanesbrands Buys Out Knights Apparel
Feb 26, 2015  
Hanesbrands Inc., a leading apparel retailer, has signed an agreement that will allow it to take over Knights Apparel for US$200 million in cash. The latter is a collegiate logo apparel seller. Analysts believe that the acquisition is a strategic one that will provide the right fit to the parent company. White Knights Apparel sells sweatshirts, T-shirts, and other sports apparel with...
Smartphone Market in India on Decline while Samsung Holds Top Spot
Feb 26, 2015  
Korean consumer electronics giant Samsung maintained its leadership in the India smartphone market. The company recorded a 22 per cent share in Q4 of 2014. The overall market has however, shrunk for the first time in history. Most manufacturers of smartphones have had a pileup of inventories in the October to December period, as said by IDC, a market research firm. The firm said that...
Apple to Face over $500 million Payout on iTunes Patent
Feb 26, 2015  
Recently, Apple was accused of using inventions knowingly which were owned by another business in iTunes. The tech giant suffered a patent loss which involved some of these technologies that were used by the iTunes store. As a result the company has been ordered to pay a fine of US$533 million to the company Smartfish. Smartfish is a company which is based in British Virgin Islands and...
Record Connection Speed Achieved by 5G Researchers
Feb 26, 2015  
A record breaking speed has been managed during the test of 5G data connection, according to scientists. The scientists at the University of Surrey’s for 5G Innovation Center or 5GIC were able to achieve a connection speed of 1 tera bit per second, which is thousands of times faster than current data connections. The head of the center at 5GIC stated that he hoped to...